CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 546 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
dCeMM2
CAS:dCeMM2 degrades glue by promoting CDK12-cyclin K ubiquitination and degradation via CRL4B ligase interaction.Formula:C16H11ClN6OSPurity:99.68%Color and Shape:SolidMolecular weight:370.82Ref: TM-T61477
1mg34.00€5mg74.00€10mg113.00€25mg236.00€50mg404.00€100mg600.00€500mg1,279.00€1mL*10mM (DMSO)104.00€hSMG-1 inhibitor 11e
CAS:hSMG-1 inhibitor 11e is an effective and selective inhibitor of hSMG-1 (IC50 <0.05 nM) and can be used in studies about cancer treatment.Formula:C26H27N7O3SPurity:99.89%Color and Shape:SolidMolecular weight:517.6CDK8-IN-1
CAS:CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).Formula:C11H8F3N3OPurity:98.48%Color and Shape:SolidMolecular weight:255.2Ref: TM-T10740
1mg87.00€5mg216.00€10mg311.00€25mg525.00€50mg707.00€100mg944.00€1mL*10mM (DMSO)240.00€DIF-3
CAS:DIF-3 activates GSK-3β, degrades cyclin D1/c-Myc, and inhibits Wnt/β-catenin in DLD-1 cells, curbing HeLa cell proliferation.Formula:C13H17ClO4Purity:99.57%Color and Shape:SolidMolecular weight:272.72Ref: TM-T60485
1mg96.00€5mg222.00€10mg333.00€25mg557.00€50mg795.00€100mg1,071.00€500mg2,187.00€1mL*10mM (DMSO)205.00€SRX3177
CAS:SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.Formula:C31H32N6O4SPurity:99.16%Color and Shape:SolidMolecular weight:584.69Ref: TM-T69742
1mg70.00€5mg150.00€10mg215.00€25mg358.00€50mg517.00€100mg707.00€1mL*10mM (DMSO)178.00€9-Isopropylolomoucine
CAS:9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.Formula:C17H22N6OPurity:99.82%Color and Shape:SolidMolecular weight:326.4Ref: TM-T23589
1mg315.00€5mg745.00€10mg1,018.00€25mg1,431.00€50mg1,783.00€100mg2,250.00€500mg4,410.00€1mL*10mM (DMSO)607.00€(S)-PF-06873600
CAS:(S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.Formula:C20H27F2N5O4SPurity:98.59%Color and Shape:SolidMolecular weight:471.52CLK-IN-T3
CAS:CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.Formula:C28H30N6O2Purity:99.61%Color and Shape:SolidMolecular weight:482.58Ref: TM-T14980
1mg47.00€2mg62.00€5mg92.00€10mg160.00€25mg289.00€50mg505.00€100mg787.00€200mg1,063.00€PS423
CAS:PS423 is a substrate-selective protein kinase PDK1 inhibitor that acts by binding to the PIF-pocket allosteric docking site.Formula:C25H23F3O9Purity:98.81% - 99.26%Color and Shape:SolidMolecular weight:524.44EHT 1610
CAS:EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively.Formula:C18H14FN5O2SPurity:98.43%Color and Shape:SolidMolecular weight:383.4BML-259
CAS:BML-259 inhibits CDK5/CDK2 (IC50: 64/98 nM) for cancer and neurodegeneration research.Formula:C14H16N2OSPurity:99.84%Color and Shape:SolidMolecular weight:260.35Ref: TM-T36964
5mg48.00€10mg80.00€25mg160.00€50mg264.00€100mg462.00€500mg982.00€1mL*10mM (DMSO)50.00€CDK9-IN-10
CAS:CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.Formula:C22H16O5Purity:99.8%Color and Shape:SolidMolecular weight:360.36Ryuvidine
CAS:Ryuvidine is a dual inhibitor of KDM5A and SETD8, an inducer of the DNA damage response, and can be used to study breast cancer and erythroderma.Formula:C15H12N2O2SPurity:98.6%Color and Shape:SolidMolecular weight:284.33Palbociclib orotate
CAS:Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively.Formula:C29H33N9O6Purity:98%Color and Shape:SolidMolecular weight:603.63CDK4-IN-2
CAS:CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].Formula:C22H26F2N6O4SPurity:98%Color and Shape:SolidMolecular weight:508.54CDK-IN-11
CAS:CDK-IN-11, a heterocyclic compound, promotes cardiomyocyte maturation [1].Formula:C25H21BrN4O2Color and Shape:SolidMolecular weight:489.36EHT 5372
CAS:EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.Formula:C17H11Cl2N5OSColor and Shape:SolidMolecular weight:404.275-Iodo-indirubin-3'-monoxime
CAS:5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50sFormula:C16H10IN3O2Color and Shape:SolidMolecular weight:403.17Leucettinib-92
CAS:Leucettinib-92 is a multi-kinase inhibitor of DYRK and CLK families with differential nanomolar activity, supporting studies of kinase signaling regulation.Formula:C21H22N4OSPurity:98%Color and Shape:SolidMolecular weight:378.49CDK9-IN-8
CAS:CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).Formula:C31H32FN7O3Purity:99.54%Color and Shape:SolidMolecular weight:569.63Voruciclib hydrochloride
CAS:Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).Formula:C22H20Cl2F3NO5Purity:98%Color and Shape:SolidMolecular weight:506.3Bisindolylmaleimide X hydrochloride
CAS:Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor. It is also a potent CDK2 antagonist (IC50: 200 nM).Formula:C26H25ClN4O2Purity:99.23%Color and Shape:SolidMolecular weight:460.96Senexin C
CAS:Senexin C is a CDK8/19 inhibitor with anticancer activity.Senexin C inhibits the growth of MV4-11 leukemia cells.Formula:C28H27N5OPurity:98.06%Color and Shape:SolidMolecular weight:449.55Cdk4 Inhibitor
CAS:PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.Formula:C20H10BrN3O2Color and Shape:SolidMolecular weight:404.2CDK9-IN-9
CAS:CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).Formula:C22H23F2N5O2SPurity:98%Color and Shape:SolidMolecular weight:459.51Lerociclib
CAS:Lerociclib (G1T38) is a CDK4/6 inhibitor with anticancer and antitumor activities, inhibiting CDK4/CyclinD1 and CDK6/CyclinD3.Formula:C26H34N8OPurity:99%Color and Shape:SolidMolecular weight:474.6(S)-Cdc7-IN-18
CAS:'(S)-Cdc7-IN-18 from patent WO2020239107A1 inhibits CDC7, curbing MCM2 and tumor growth.'Formula:C19H21N5OSColor and Shape:SolidMolecular weight:367.47CDK4/6-IN-17
CAS:CDK4/6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4/6, demonstrating potent activity with IC50 values between 10-100 nM in BE(2) cells.Formula:C27H28F4N8Purity:98%Color and Shape:SolidMolecular weight:540.56CDK8-IN-3
CAS:CDK8-IN-3 is an inhibitor of CDK8.Formula:C22H23N5O2Purity:98%Color and Shape:SolidMolecular weight:389.45CDK/HDAC-IN-3
CAS:CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3,Formula:C24H18Cl2N6O3Purity:98%Color and Shape:SolidMolecular weight:509.34Xylocydine
CAS:Xylocydine is a novel Cdk inhibitor that induces apoptosis in HCC, suppresses tumor growth, and is non-toxic to other tissues.Formula:C12H14BrN5O5Color and Shape:SolidMolecular weight:388.17Cdc7-IN-12
CAS:Cdc7-IN-12, a sub-1 nM CDC7 inhibitor, may aid cancer research; hinders COLO205 cell growth (IC50: 100-1000 nM).Formula:C16H14N2O2SColor and Shape:SolidMolecular weight:298.36QR-6401
CAS:QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/Formula:C19H23N5O3Purity:98%Color and Shape:SolidMolecular weight:369.42Senexin A hydrochloride
CAS:Senexin A hydrochloride functions as a selective inhibitor of CDK8/19, with an IC 50 of 280 nM for CDK8, and specifically inhibits p21-induced transcription without affecting other biological effects of p21. Additionally, it suppresses CMV-GFP induction and the stimulatory activity of the consensus NF-κB-dependent promoters [1] [2].Formula:C17H15ClN4Color and Shape:SolidMolecular weight:310.78Nε-(1-Carboxyethyl)-L-lysine
CAS:Nε-(1-Carboxyethyl)-L-lysine (CEL) is an advanced glycation end-product (AGE). Exposure to CEL reduces glutamate uptake and S100B secretion in the hippocampus.Formula:C9H18N2O4Color and Shape:SolidMolecular weight:218.25Tacaciclib
CAS:Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].Formula:C30H36N6O3Purity:98%Color and Shape:SolidMolecular weight:528.65CDK4/6-IN-15
CAS:CDK4/6-IN-15: Oral, selective CDK4/6 inhibitor, halts cancer cell growth, G1 arrest, suppresses Rb phosphorylation.Formula:C21H27FN8SColor and Shape:SolidMolecular weight:442.56LDC3140
CAS:LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7).Formula:C23H33N7OPurity:98%Color and Shape:SolidMolecular weight:423.55PF-6808472
CAS:PF-6808472 is a cell-permeable covalent kinase probe, reacts with conserved lysine residues within the ATP-binding site of kinases.Formula:C25H27FN8O3SPurity:99.02%Color and Shape:SolidMolecular weight:538.6CDK9-IN-19
CAS:CDK9-IN-19: Potent CDK9 inhibitor, anti-cancer, moderate pharmacokinetics, low hERG impact, effective in AML research.Formula:C26H22F2N4O5Color and Shape:SolidMolecular weight:508.47Mevociclib
CAS:Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.Formula:C31H35ClN8O2Purity:98.02% - 98.02%Color and Shape:SolidMolecular weight:587.11CDK7-IN-14
CAS:CDK7-IN-14 (compound 3) is a pyrimidine-derived CDK7 inhibitor applicable for studying cancers associated with transcriptional dysregulation.Formula:C22H24F3N6OPPurity:99.24% - 99.48%Color and Shape:SolidMolecular weight:476.43SZ-015268
CAS:SZ-015268: CDK7 inhibitor, IC50=23.56 nM; hinders HCC70, OVCAR-3, HCT116, HCC1806 cell growth; strong anti-tumor effect.Formula:C25H38N8O3Color and Shape:SolidMolecular weight:498.62Riviciclib
CAS:Riviciclib, a CDK inhibitor (CDK9/T1, CDK4/D1, CDK1/B), has IC50s: 20, 63, 79 nM respectively, and fights cisplatin-resistant tumors.Formula:C21H20ClNO5Purity:98%Color and Shape:SolidMolecular weight:401.84ML 315 hydrochloride
CAS:ML 315, a selective dual inhibitor targeting CDK (Cyclin-Dependent Kinase) and DYRK (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase) with IC50 values of 68 nM and 282 nM, respectively, is utilized in research pertaining to cancer and neurological diseases [1].
Formula:C18H14Cl3N3O2Color and Shape:SolidMolecular weight:410.682CDK9-IN-2
CAS:CDK9-IN-2, a CDK9 inhibitor from patent WO/2012131594A1, IC50: 5 nM in A2058, 7 nM in H929 at 72hr.Formula:C23H25ClFN5Purity:99%Color and Shape:SolidMolecular weight:425.93Ref: TM-T14918
1mg84.00€5mg177.00€10mg266.00€25mg460.00€50mg668.00€100mg945.00€1mL*10mM (DMSO)195.00€CDK7-IN-22
CAS:CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].Formula:C22H25F3N6Purity:98%Color and Shape:SolidMolecular weight:430.47HQ005
CAS:HQ005, a potent CCNK degrader, exhibits an impressive DC50 value of 0.041 µM and functions as a molecular-glue degrader.Formula:C15H15N5O2S2Color and Shape:SolidMolecular weight:361.44Inixaciclib
CAS:Inixaciclib is a potent CDK inhibitor, can be used to research anticancer.Formula:C26H30F2N6OColor and Shape:SolidMolecular weight:480.55NU6300
CAS:NU6300 is a covalent CDK2 inhibitor exhibiting irreversible and ATP-competitive properties and also functions as a GSDMD (Gasdermin D) inhibitor.Formula:C20H23N5O3SPurity:96.08%Color and Shape:SolidMolecular weight:413.49CDK7-IN-25
CAS:CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].Formula:C33H32N6O3Purity:98%Color and Shape:SolidMolecular weight:560.65IIIM-290
CAS:IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).Formula:C23H21Cl2NO5Purity:98%Color and Shape:SolidMolecular weight:462.32Cdc7-IN-7
CAS:Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.
Formula:C21H22N4O5Purity:98.78%Color and Shape:SolidMolecular weight:410.42CDK9-IN-29
CAS:CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM.Formula:C29H33F2N5O4Purity:98%Color and Shape:SolidMolecular weight:553.6SHP2/CDK4-IN-1
CAS:SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.Formula:C33H35ClF2N10OSColor and Shape:SolidMolecular weight:693.21DCB-3503
CAS:DCB-3503, a tylophorine analog, may fight cancer and aid immunosuppression by hindering protein synthesis and modulating HSC70 ATPase function.Formula:C24H27NO5Color and Shape:SolidMolecular weight:409.47KM05382
CAS:KM05382 inhibits CDK9 and the transcription of GAPDH.Formula:C20H19ClN2O3S2Color and Shape:SolidMolecular weight:434.96CDK9-IN-23
CAS:CDK9-IN-23 (Example 4) is a potent inhibitor of CDK9, exhibiting an IC50 value of less than 20 nM [1].Formula:C22H25ClN4O3Purity:98%Color and Shape:SolidMolecular weight:428.91(2S,3R)-Voruciclib
CAS:(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.Formula:C22H19ClF3NO5Purity:98%Color and Shape:SolidMolecular weight:469.84CCT-251921
CAS:CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).Formula:C21H23ClN6OPurity:99.07%Color and Shape:SolidMolecular weight:410.9Ref: TM-T14901
1mg90.00€5mg210.00€10mg308.00€25mg520.00€50mg745.00€100mg1,018.00€1mL*10mM (DMSO)192.00€AZD4573
CAS:AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.Formula:C22H28ClN5O2Purity:99% - 99.51%Color and Shape:SolidMolecular weight:429.94XY028-140
CAS:XY028-140 is a selective CDK4/6 inhibitor and degrader, acting via PROTAC with ligands for Cereblon and CDK in cancer cells.Formula:C39H40N10O7Purity:98.59%Color and Shape:SolidMolecular weight:760.8Debio-0123
CAS:Debio-0123: potent, specific oral WEE1 inhibitor; IC50 in low nanomolar; boosts DNA damage & Carboplatin's anti-cancer effects.Formula:C26H28Cl2N6OPurity:99.93%Color and Shape:SolidMolecular weight:511.45(R)-Simurosertib
CAS:(R)-Simurosertib ((R)-TAK-931) is an inhibitor of the ATP-competitive cell division cycle 7 (CDC7) kinase.Formula:C17H19N5OSPurity:99.89%Color and Shape:SolidMolecular weight:341.43Cdk1/2 Inhibitor III
CAS:Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor with an IC50 value of 2.1 μM against CDK1/cyclin B.Formula:C15H13F2N7O2S2Purity:99.92%Color and Shape:SolidMolecular weight:425.44CF53
CAS:CF53: potent, selective oral BET inhibitor; Ki <1 nM, Kd 2.2 nM, IC50 2 nM for BRD4 BD1; high affinity for BRD2/3/4/BRDT; effective anti-tumor agent.Formula:C24H25N7O2Purity:99.72%Color and Shape:SolidMolecular weight:443.5Ref: TM-T10773
1mg92.00€5mg200.00€10mg299.00€25mg484.00€50mg658.00€100mg892.00€1mL*10mM (DMSO)215.00€CDK2-IN-18
CAS:CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].Formula:C21H23N7O2SColor and Shape:SolidMolecular weight:437.52CDK2 degrader 6
CAS:CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.Formula:C23H22F5N5O3Color and Shape:SolidMolecular weight:511.44INX-315
CAS:INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.Formula:C19H21N7O3SPurity:99.88%Color and Shape:SolidMolecular weight:427.48Tizolemide
CAS:Tizolemide, a sulfonamide diuretic compound with alkaline properties, is cleared through the tubular transport system. It induces changes in the passive transport components across the basolateral membrane of isolated frog skin.Formula:C11H14ClN3O3S2Color and Shape:SolidMolecular weight:335.83CDDD11-8
CAS:CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].Formula:C24H26N6Color and Shape:SolidMolecular weight:398.50Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Formula:C12H8N4O2SColor and Shape:SolidMolecular weight:272.28CDK1-IN-4
CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.Formula:C26H24ClN5SColor and Shape:SolidMolecular weight:474.02CDK12/13 ligand 1
CAS:ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.Formula:C26H26BrN5OColor and Shape:SolidMolecular weight:504.42CDK2-IN-31
CAS:CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.Formula:C37H52N6O5Color and Shape:SolidMolecular weight:660.85SGC-CLK-1
CAS:SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.Formula:C19H15F3N6O2Color and Shape:SolidMolecular weight:416.36CDK8-IN-5
CAS:CDK8-IN-5: potent CDK8 inhibitor, IC50=72 nM, boosts IL-10 by 43%, may aid inflammatory bowel disease research.Formula:C26H22N2O4Color and Shape:SolidMolecular weight:426.46PROTAC CDK12/13 Degrader-1
PROTAC CDK12/13 Degrader-1 (7f) selectively degrades CDK12/13 at nanomolar potency, targeting breast cancer.Color and Shape:SolidCDK8-IN-11 hydrochloride
CDK8-IN-11 HCl: potent, selective CDK8 inhibitor (IC50: 46 nM), blocks WNT/β-catenin pathway, used in colon cancer research.Formula:C19H16ClF3N4O2Color and Shape:SolidMolecular weight:424.8CDK9-IN-34
CAS:CDK9-IN-34 (Compound 1b) is an inhibitor of CDK9 with an IC50 of 0.25 μM. It exhibits cytotoxicity against cancer cell lines HCT116, MCF7, and K652, with IC50 values of 1.43 μM, 3.01 μM, and 50.27 μM, respectively. Additionally, CDK9-IN-34 demonstrates antiviral activity against coronavirus 229E with an IC50 of 145.92 μM.Formula:C18H20N4Color and Shape:SolidMolecular weight:292.38RGB-286638
CAS:RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.Formula:C29H37Cl2N7O4Color and Shape:SolidMolecular weight:618.55CDK8-IN-11
CAS:CDK8-IN-11 is a CDK8 inhibitor that demonstrates anti-proliferative activity against colon cancer cell lines and inhibits the activation of WNT/β-catenin.Formula:C19H15F3N4O2Purity:99.74%Color and Shape:SolidMolecular weight:388.34Ref: TM-T61742
1mg54.00€5mg114.00€10mg178.00€25mg409.00€50mg708.00€100mg982.00€1mL*10mM (DMSO)126.00€Cdc7-IN-10
CAS:Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.Formula:C20H22F2N4O2SColor and Shape:SolidMolecular weight:420.48Haspin-IN-2
CAS:Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).Formula:C12H8N4O3Color and Shape:SolidMolecular weight:256.22Cdc7-IN-8
CAS:Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)Formula:C19H21N5O2Color and Shape:SolidMolecular weight:351.40CDK7-IN-17
CAS:CDK7-IN-17 (compound 11) is a pyrimidine-derived CDK7 inhibitor for studying transcription-disrupted cancers.Formula:C24H26F3N6OPPurity:99.60%Color and Shape:SolidMolecular weight:502.47CDK7/12-IN-1
CAS:CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.Formula:C25H34N8OColor and Shape:SolidMolecular weight:462.59DS96432529
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.Formula:C18H26N4O3SColor and Shape:SoildMolecular weight:378.49Cdc7-IN-11
CAS:Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.Formula:C20H22F2N4O2SColor and Shape:SolidMolecular weight:420.48CLK1/4-IN-1
CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.Formula:C18H14ClNO4SColor and Shape:SolidMolecular weight:375.83CDK9-IN-13
CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.Formula:C27H35N5O2Color and Shape:SolidMolecular weight:461.6CDK1-IN-3
CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.Formula:C28H25ClF3N5O2Color and Shape:SolidMolecular weight:555.98CDK/HDAC-IN-1
CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.Formula:C20H18N4O4Color and Shape:SolidMolecular weight:378.38CDK7-IN-33
CAS:CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.Formula:C29H36N6O4SColor and Shape:SolidMolecular weight:564.699CDK8-IN-9
CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.Color and Shape:SolidYL-1-9
CAS:YL-1-9 is an inhibitor that prevents the degradation of p53 by MDM2 through tight binding to the crucial hydrophobic pocket of MDM2. It can induce cell cycle arrest and apoptosis in breast cancer cells [1].Formula:C22H23F3N2O3Color and Shape:SolidMolecular weight:420.425CLK1/2-IN-1
CAS:CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.Formula:C21H20F3N7OPurity:98%Color and Shape:SolidMolecular weight:443.42GSK3-IN-10
CAS:GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.Formula:C17H18F2N4O3Color and Shape:SolidMolecular weight:364.347CDK4/6-IN-13
CAS:Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.Formula:C25H29N7OColor and Shape:SolidMolecular weight:443.54Anticancer agent 29
Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).Formula:C22H15ClFNOColor and Shape:SolidMolecular weight:363.81
